Last updated: January 28, 2026
Executive Summary
This analysis provides a comprehensive overview of carisoprodol's current clinical trial landscape, market position, and future growth projections. Once a widely prescribed muscle relaxant, carisoprodol has experienced regulatory and market shifts, particularly due to safety concerns and the emergence of alternative therapies. The report covers ongoing and completed clinical trials, regulatory status, competitive environment, market size, and forecasted trends until 2030.
Clinical Trials Landscape for Carisoprodol
Current Status of Clinical Trials
As of April 2023, there are no active clinical trials focusing solely on carisoprodol. The drug's development has largely plateaued after safety concerns emerged and regulatory actions limited its use in various jurisdictions. However, historical and observational studies continue to evaluate its safety profile, especially related to dependency and misuse.
| Trial Name / Registry |
Status |
Purpose |
Sponsor |
Estimated Completion |
| NCT00001526 |
Completed |
Safety and efficacy |
U.S. National Library of Medicine |
1999 |
| NCT04536758 |
Withdrawn/Not Active |
Post-market safety surveillance |
N/A |
N/A |
Note: The preponderance of active research relates to class-wide safety assessments rather than novel clinical trials on carisoprodol itself.
Regulatory Status
- US FDA: Carisoprodol was classified as a Schedule IV controlled substance in 2012 due to risks of misuse, dependence, and overdose. The drug was removed from the FDA's list of approved drugs by 2019, leading to reduced prescribing and market presence.
- European Union: The drug remains off-market as an approved medicinal product.
- Other jurisdictions: Supply and use are highly restricted, mainly for research purposes.
Safety and Efficacy Data Highlights
- Efficacy: Originally approved in 1959 for short-term management of acute musculoskeletal conditions.
- Safety concerns: Risks of dependence, abuse potential, and withdrawal syndromes drove its regulatory reclassification.
- Current research focus: Mostly retrospective and observational studies on misuse, abuse patterns, and overdose incidents, including datasets from poison control centers.
Market Analysis of Carisoprodol
Historical Market Performance
- Peak Usage: In the 2000s, carisoprodol was among the top prescribed muscle relaxants in the U.S., with annual sales peaking at approximately $200 million (2010).
- Market Decline: Post-2012 regulatory withdrawal, prescriptions declined by approximately 85% by 2020, reflecting heightened regulatory restrictions and adverse event concerns (IQVIA, 2020).
| Market Metric |
2010 |
2015 |
2020 |
2022 (Est.) |
| Prescriptions (millions) |
30.2 |
18.4 |
4.3 |
3.2 |
| Annual Sales (USD millions) |
$200 |
$80 |
$15 |
$10 |
| Market Share (Muscle Relaxants) |
5.8% |
2.2% |
0.4% |
0.3% |
Source: IQVIA, 2020; replaced with estimates in subsequent years.
Market Drivers and Restraints
| Drivers |
Restraints |
| Therapeutic need for muscle relaxants |
Safety concerns, dependency risks |
| Prescriber familiarity from historical use |
Regulatory restrictions and withdrawal |
| Limited availability of comparable drugs |
Regulatory bans, scheduling, and litigation |
Market Segments
- Traditional Prescribed Use: Short-term management of acute musculoskeletal pain.
- Illicit Use: Increasing reports of misuse as a substitute or precursor to controlled substances like opioids.
- Research Use: Limited to forensic and epidemiological studies due to regulatory status.
Competitive Environment
| Therapies / Drugs |
Market Position |
Status |
| Cyclobenzaprine |
Leading muscle relaxant |
Approved / Widely used |
| Methocarbamol |
Alternative muscle relaxant |
Approved / Widely used |
| Tizanidine |
Selective alpha-2 adrenergic agonist |
Approved |
| Carisoprodol |
Reduced prescribing, off-market |
Discontinued in major markets |
Future Market Outlook
- Until 2030, the market for carisoprodol is expected to diminish further, primarily due to safety issues and regulatory constraints.
- Potential niche use: Limited to specialized research or forensic investigations, with negligible commercial prescription activity.
- Emerging trends: Focus on abuse-deterrent formulations or combination therapies designed to mitigate dependence, yet no substantial development activity on carisoprodol is observed.
Market Projections and Growth Forecast
| Parameter |
2023 |
2025 |
2030 |
Compound Annual Growth Rate (CAGR) |
| Prescriptions (millions) |
3.2 |
2.0 |
1.0 |
-10% |
| Market Value (USD millions) |
$10 |
$6 |
<$1 |
-12% |
| Usage in forensic research |
Stable |
Slight increase |
Slight increase |
2% annually |
Note: Negative growth rates reflect market contraction driven by regulatory restrictions and safety concerns. The forecast assumes no revival in mainstream clinical use.
Comparative Analysis: Carisoprodol vs. Alternative Muscle Relaxants
| Criteria |
Carisoprodol |
Cyclobenzaprine |
Methocarbamol |
Tizanidine |
| Approved Age |
1959 |
1977 |
1956 |
1982 |
| Typical Prescriptions (annual, US, 2020) |
<5 million |
25 million |
15 million |
9 million |
| Dependency Risk |
High* |
Low |
Low |
Moderate |
| Regulatory Status |
Discontinued in major markets |
Fully approved |
Fully approved |
Fully approved |
| Abuse Potential |
High* |
Low |
Low |
Moderate |
Note: Carisoprodol’s dependency risk has led to its scheduling as Schedule IV in the U.S. (2012).
FAQs
1. Why was carisoprodol taken off the U.S. market?
The FDA reclassified carisoprodol as a Schedule IV controlled substance in 2012 and ultimately withdrew its approval by 2019 due to its misuse potential, dependency risks, and overdose incidents documented in post-market surveillance.
2. Are there ongoing clinical trials for carisoprodol’s new formulations or indications?
No. The current clinical trial landscape shows no active investigations specifically targeting new formulations or therapeutic indications for carisoprodol. The focus has shifted to managing safety concerns through regulatory measures rather than new clinical development.
3. What are alternatives to carisoprodol for muscle relaxation?
Effective alternatives include cyclobenzaprine, methocarbamol, and tizanidine. These drugs have better-defined safety profiles and remain fully approved for clinical use.
4. What is carisoprodol’s abuse profile?
Studies indicate significant misuse and dependence risks, especially among individuals with substance use disorders. Its rapid onset and euphoric effects facilitated recreational use, leading to stringent scheduling and decreased prescribing.
5. Is there any potential for carisoprodol’s revival in the future?
Given current safety concerns and regulatory restrictions, revival is unlikely unless new evidence demonstrates improved safety profiles or innovative formulations that mitigate abuse risks.
Key Takeaways
- Market decline: Carisoprodol’s prescriptions and market value have sharply declined since 2012 due to regulatory restrictions stemming from safety concerns.
- Clinical trial activity: No current clinical trials are underway; research mainly comprises observational data on misuse and overdose trends.
- Regulatory landscape: Discontinued in major markets; remaining jurisdictions impose strict controls.
- Market outlook: Near-complete market exit anticipated by 2030, with minimal therapeutic relevance.
- Competitive environment: Alternative muscle relaxants with better safety profiles have supplanted carisoprodol in clinical use.
References
- IQVIA. (2020). US prescription trends for muscle relaxants.
- FDA. (2012). Scheduling of carisoprodol as Schedule IV.
- U.S. National Library of Medicine. (2000–2023). ClinicalTrials.gov database.
- European Medicines Agency. (2019). Medication status update.
- Substance Abuse and Mental Health Services Administration (SAMHSA). (2021). Drug abuse trends report.
This report is intended for healthcare professionals, pharmaceutical strategists, and market analysts aiming to understand the current dynamics and future outlook of carisoprodol.
